KRAS Alleles and Genomic Testing in Pancreatic Cancer

Dr Lee, a gastrointestinal medical oncologist at Stanford University, gives a primer on reading KRAS results on a next-generation sequencing report, explaining that the letter, number, letter format identifies the codon and the amino acid change. Most pancreatic ductal adenocarcinoma mutations involve the same glycine residue, with G12D the most common, followed by G12V and G12R, while G12C, familiar from lung cancer, is uncommon here. He notes retrospective evidence that alleles differ prognostically, differing sensitivity to KRAS inhibitors, and active trial development around specific alleles. Dr Balmaceda, a gastrointestinal medical oncologist at MD Anderson Cancer Center, adds that co-mutations in TP53, CDKN2A, and SMAD4 affect genomic stability, cell cycle regulation, and the tumor microenvironment, but are not yet used to select standard therapy. Dr Lee closes by urging comprehensive sequencing at diagnosis, noting platinum sensitivity conferred by DNA repair gene mutations, and cautioning that a negative liquid biopsy cannot rule out mutations because pancreatic tumors shed little circulating tumor DNA.